Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study.

Abstract

One hundred and nine elderly patients suffering from mild to moderate cognitive impairment fulfilling NINCDS-ADRDA criteria for probable dementia of the Alzheimer type were treated for 6 months with a new nootropic drug, aniracetam (Ro 13-5057) in a double-blind randomized study versus placebo. The two treatment groups were comparable at baseline for demographic and behaviourial parameters and symptomatology. Patients underwent clinical, behaviourial and psychometric evaluation every other month. The aniracetam group differed significantly from the placebo group by the end of the study and also showed a statistically significant improvement versus baseline in the psychobehavioural parameters, while in the placebo group a steady deterioration was observed. Tolerability to aniracetam was excellent.

• Authors: U Senin, G Abate, C Fieschi, G Gori, A Guala, G Marini, C Villardita, L Parnetti
• Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (Eur Neuropsychopharmacol) Vol. 1 Issue 4 Pg. 511-7 (Dec 1991) ISSN: 0924-977X [Print] Netherlands
• PMID: 1822317 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Pyrrolidinones
• aniracetam

Topics

• Aged
• Aged, 80 and over
• Alzheimer Disease (drug therapy, psychology)
• Behavior (drug effects)
• Double-Blind Method
• Female
• Humans
• Male
• Patient Compliance
• Psychiatric Status Rating Scales
• Pyrrolidinones (adverse effects, therapeutic use)